SCHEMBL4670184

SCHEMBL4670184

CCc1oc2ccccc2c1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EYA3 Q99504 5/20 0.66
SLC22A12 Q96S37 3/20 0.66
CYP2C19 P33261 7/20 0.61
CYP2C9 P11712 7/20 0.61
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
ABCB11 O95342 2/20 0.61
LMNA P02545 2/20 0.61
TTR P02766 2/20 0.61
PGR P06401 2/20 0.61
ADRA2A P08913 2/20 0.61
TBXA2R P21731 2/20 0.61
OPRM1 P35372 2/20 0.61
SLC6A3 Q01959 2/20 0.61
BIRC5 O15392 1/20 0.61
HTR1A P08908 1/20 0.61
DRD1 P21728 1/20 0.61
PTGS1 P23219 1/20 0.61
SLC6A2 P23975 1/20 0.61
PDE4A P27815 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9350957 0.98 EYA3 (0.64) EYA3SLC22A12CYP2C19CYP2C9KMT2A
SCHEMBL9760347 0.89 CYP2C9 (0.68) EYA3SLC22A12CYP2C19CYP2C9KMT2A
SCHEMBL27935343 0.88 EYA3 (0.77) EYA3SLC22A12CYP2C19CYP2C9KMT2A
SCHEMBL1287913 0.87 EYA3 (0.81) EYA3SLC22A12CYP2C19CYP2C9KMT2A
SCHEMBL28101771 0.86 EYA3 (0.79) EYA3SLC22A12CYP2C19CYP2C9KMT2A
Hydrochloric Acid SCHEMBL9347221 0.85 CYP2C9 (0.58) EYA3SLC22A12CYP2C19CYP2C9KMT2A
SCHEMBL28131231 0.85 EYA3 (0.64) EYA3SLC22A12CYP2C19CYP2C9KMT2A
SCHEMBL4670709 0.85 EYA3 (0.64) EYA3SLC22A12CYP2C19CYP2C9KMT2A
SCHEMBL2944813 0.84 PTPN1 (0.69) EYA3TTRNR1H4PTPN1THRB
Hydrochloric Acid SCHEMBL9347277 0.83 PTPN1 (0.67) EYA3KMT2AMEN1LMNATTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397341-B1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH CORP (US) 2008-08-06 EP claimed
EP-1397341-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) Wyeth (US) 2004-03-17 EP claimed
US-6589970-B2 This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: WYETH 2003-07-08 US claimed
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) WYETH 2003-03-06 US claimed
WO-2003000649-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH (US) 2003-01-03 WO claimed
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-17 US disclosed
US-20230241025-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-03 US disclosed
EP-1397341-B1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH CORP (US) 2008-08-06 EP disclosed
EP-1397341-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) Wyeth (US) 2004-03-17 EP disclosed
US-6589970-B2 This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: WYETH 2003-07-08 US disclosed
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) WYETH 2003-03-06 US disclosed
WO-2003000649-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241025-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS FABP1, FABP4, FABP5 EYA3 3453/4885SLC22A12 2821/4885CYP2C19 4420/4885
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) SERPINC1, F11, SERPINE1 EYA3 3991/4885SLC22A12 3642/4885CYP2C19 1188/4885
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS FABP1, FABP4, FABP5 EYA3 3562/4885SLC22A12 2093/4885CYP2C19 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.